HEART FAILURE AT CROSSROADS Bergamo (Italy), November 27th - 29th, 2014 Organized by CLINICAL RESEARCH FOUNDATION, BERGAMO HOSPITAL (FROM) AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII - BERGAMO Promoted by Under the Auspice of FIC – Italian Federation of Cardiology FINAL PROGRAM Teatro Sociale Via Colleoni, 4 - Bergamo HEART FAILURE AT CROSSROADS Bergamo (Italy), November 27th - 29th, 2014 Organized by CLINICAL RESEARCH FOUNDATION, BERGAMO HOSPITAL (FROM) AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII - BERGAMO Promoted by Under the Auspice of FIC – Italian Federation of Cardiology FINAL PROGRAM Teatro Sociale Via Colleoni, 4 - Bergamo Heart Failure (HF) is a global pandemic affecting an estimated 26 million people worldwide and resulting in millions of hospitalizations globally. Although the outcomes for ambulatory HF patients with a reduced ejection fraction have improved with the discovery of multiple evidence-based drug and device therapies, worsening HF patients continue to experience unacceptably high mortality and readmission rates that have not changed in the last two decades. It is important to note that half of patients with worsening HF have preserved ejection fraction and have similarly high event-rates for whom there are no evidence-based therapies to improve outcomes. HF registries have significantly improved our understanding of this clinical entity and remain an important source of data shaping both public policy and research efforts. Therefore, it is of utmost importance to re-evaluate what is known, identify what is not known, and develop a roadmap for the improving outcomes through better understanding of the disease process in order to identify unique targets for different HF populations. It is essential to “find the disease” within HF. The typical example is Diabetes, where worsening HF develops on a different myocardial substrate characterized by specific myocardial metabolic, functional, neurohormonal and hemodynamic changes, may respond differently to certain HF therapies and shows unacceptably high morbidity and mortality rates compared to HF without DM. One-size fits all approach is doubtful to lead to a substantial improvement in outcomes. The goals of this meeting will be to discuss and summarize current status of HF and to develop a roadmap for clinical practice and research. Bergamo has a longstanding tradition in cardiovascular research and in the new Hospital Papa Giovanni XXIII a research Center devoted to HF has been established. For these reasons Bergamo represents a perfect location for an update on HF programs. Antonello Gavazzi, Mihai Gheorghiade, Michele Senni Course Meeting Directors –2– Under the Auspice of FIC – Italian Federation of Cardiology Antonello Gavazzi FROM Foundation for Research Bergamo, I Course Meeting Directors Michele Senni Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo, I Mihai Gheorghiade Experimental Therapeutics, Center for Cardiovascular Innovation Northwestern University Feinberg School of Medicine Chicago, USA Scientific Secretary Marilisa Ambrosio Azienda Ospedaliera Papa Giovanni XXIII Bergamo, I Fumiko Inoue Project Organizer Logica Med Promoted by Fondazione Internazionale Menarini Edificio L – Strada 6 Centro Direzionale Milanofiori I-20089 Rozzano (Milan, Italy) Phone: +39 02 55308110 Fax: +39 02 55305739 E-mail: milan@fondazione-menarini.it Http://www.fondazione-menarini.it Organizing Secretariat Servizi C.E.C. S.r.l. Via Verdi, 18 I-24121 Bergamo (Italy) Phone: +39 035 249899 Provider ECM MZ Congressi S.r.l. Provider accreditato n. 966 Via Carlo Farini, 81 I-20159 Milan (Italy) Phone: +39 02 66802323 –3– Thursday, November 27th, 2014 – Afternoon 04.00 p.m. - 05.00 p.m. Saluti di Benvenuto / Welcome Addresses Alessandro Casini, President of “Fondazione Internazionale Menarini” Carlo Nicora, General Director, “Ospedale Papa Giovanni XXIII”, Bergamo Tiziano Barbui, Scientific Director, FROM Fondazione per la Ricerca, Ospedale Papa Giovanni XXIII, Bergamo Antonello Gavazzi, FROM Fondazione per la Ricerca, Ospedale Papa Giovanni XXIII, Bergamo Michele Senni, Cardiologia 1 – Scompenso e Trapianti di Cuore, Ospedale Papa Giovanni XXIII, Bergamo 05.00 p.m. - 06.00 p.m. Lettura Magistrale / Keynote Address Mihai Gheorghiade Heart Failure Research over the last 10 years: the Last Unconquered Frontier in Cardiology 06.00 p.m. - 06.30 p.m. Question and answers Discussion 06.30 p.m. - 08.00 p.m. Tavola rotonda sui “Network di Patologia” / Round Table on “Pathology Networks” Mihai Gheorghiade, Michele Senni, Antonello Gavazzi, Tiziano Barbui –4– Friday, November 28th, 2014 – Morning Session I: Worsening Heart Failure 08.30 a.m. - 08.45 a.m. Claudia Vittori Case Presentation Discussant: Michele Emdin Chairpersons: 08.45 a.m. - 09.00 a.m. 09.00 a.m. - 09.15 a.m. 09.15 a.m. - 09.30 a.m. 09.30 a.m. - 10.00 a.m. 10.00 a.m. - 10.30 a.m. Andrea Di Lenarda Giuseppe Ambrosio Javed Butler What is worsening heart failure? Definition, epidemiology and classification Mihai Gheorghiade Worsening chronic heart failure: end stage disease or salvageable? Aldo Pietro Maggioni Worsening hospitalized heart failure: finally a surrogate marker among hospitalized heart failure patients? Discussion Coffee break –5– Friday, November 28th, 2014 – Morning Session II: New Target - New Therapies 10.30 a.m. - 10.45 a.m. Emilia D’Elia Case presentation Discussant: Elisabeth K. Krainer Chairpersons: 10.45 a.m. - 11.00 a.m. 11.00 a.m. - 11.15 a.m. 11.15 a.m. - 11.30 a.m. 11.30 a.m. - 12.00 a.m. Giuseppe Di Tano Maurizio Porcu Adrian Voors Targets to develop novel heart failure therapies – returning to the heart Javier Diez The next decade of trials and therapies for heart failure with reduced ejection fraction Marco Metra Hospitalized heart failure: acute therapies, chronic therapies, or bridging therapies? Discussion 12.00 a.m. - 02.00 p.m. Lunch –6– Friday, November 28th, 2014 – Afternoon Session III: Chairpersons: Beyond Drugs – Alternative Therapeutics Options Luca Ferdinando Lorini Fabrizio Oliva 02.00 p.m. - 02.15 p.m. Attilio Iacovoni Case presentation Discussant: Francesco Grigioni 02.15 p.m. - 02.30 p.m. Andrea Mortara Ambulatory monitoring – options and outcomes 02.30 p.m. - 02.45 p.m. Gaetano Maria De Ferrari The future of stem cell therapy for heart failure 02.45 p.m. - 03.00 p.m. Maria Frigerio Circulatory support future 03.00 p.m. - 03.15 p.m. Alec Vahanian MitraClip 03.15 p.m. - 03.45 p.m. Discussion 03.45 p.m. - 04.15 p.m. Coffee break –7– Friday, November 28th, 2014 – Afternoon Session IV: Chairpersons: Heart Failure with preserved ejection fraction: New directions Massimo Volpe Nadia Aspromonte 04.15 p.m. – 04.30 p.m. Michele Senni Lessons learned from heart failure with preserved ejection fraction trials 04.30 p.m. - 04.45 p.m. Burkert Mathias Pieske Next Steps: Outpatient versus Hospitalized patient 04.45 p.m. – 05.15 p.m. Mauro Gori, Aurelia Grosu Cases presentation Discussant: Marco Guazzi, Javier Diez 05.15 p.m. – 06.30 p.m. Questions and answers Discussion –8– Saturday, November 29th, 2014 – Morning Session V: Chairpersons: HF in patients with Diabetes Mellitus: a distinct entity Cheuk-Man Yu Naoki Sato 08.00 p.m. – 08.15 a.m. Alice Calabrese Case presentation Discussant: Renata De Maria 08.15 p.m. – 08.30 a.m. Alessandra Dei Cas Epidemiology and significance 08.30 a.m. – 08.45 a.m. Giovanni Cioffi Pathophysiology of heart failure with diabetes mellitus 08.45 a.m. – 09.00 a.m. Ovidiu Chioncel The role of kidney in patients with diabetes mellitus and heart failure 09.00 a.m. – 09.15 a.m. Roberto Trevisan Treatment of diabetes mellitus in patients with heart failure 09.15 a.m. – 09.30 a.m. Frank Edelmann Treatment of heart failure in patients with diabetes mellitus and future directions 09.30 a.m. – 10.15 a.m. 10.15 a.m. – 10.30 a.m. Discussion Coffee break –9– Saturday, November 29th, 2014 – Morning Session VI: Chairpersons: Workshop: clinical trials and future directions Savina Nodari Mihai Gheorghiade 10.30 a.m. – 10.45 a.m. Robert O. Bonow Lessons learned from past heart failure trials 10.45 a.m. – 11.00 a.m. Mihai Gheorghiade Proof of concepts study – from animal models to human models and the role of T1 centers 11.00 a.m. – 11.15 a.m. Antonello Gavazzi Matching the drug with the right patients population 11.15 a.m. – 11.30 a.m. Luigi Tavazzi What are the appropriate endpoints for heart failure trials 11.30 a.m. – 11.45 a.m. Cheuk-Man Yu Trial execution enrollment, retention 11.45 a.m. – 12.45 p.m. Lessons from Registries: Andrew Ambrosy, Ovidiu Chioncel, Naoki Sato, Luigi Tavazzi Globalization of heart failure trials: good or bad? 12.45 p.m. – 01.45 p.m. Discussion 01.45 p.m. – 02.05 p.m. Conclusion and Future Directions Antonello Gavazzi, Mihai Gheorghiade, Michele Senni 02.05 p.m. – 03.35 p.m. CME/ECM questionnaires – 10 – GENERAL INFORMATION Meeting venue The venue for the Meeting will be Teatro Sociale, Via Colleoni, 4, Bergamo (Italy). Secretariat during the Meeting The Secretariat will be open at the following times: Thursday, November 27th, from 03.30 p.m. to 08.00 p.m. Friday, November 28th, from 08.00 a.m. to 06.30 p.m. Saturday, November 29th, from 08.00 a.m. to 12.30 a.m. Official language The official language of the Meeting will be English. Registration The Meeting is free to attend. Please confirm the participation to (Fondazione Internazionale Menarini, Phone: +39 02 55308110 - Fax: +39 02 55305739 E-mail: milan@fondazione-menarini.it). Italian CME Accreditation The application for CME accreditation has been submitted with 8,5 credits for Italian Physicians and Pharmacist (Cardiology, Pharmacy, General Medicine). The CME credits will be recognized only after full attendance of all sessions and a minimum score of 75% of correct answers in the learning questionnaires. Completion of the Registration Form, the Learning & Assessment questionnaires are compulsory. For information on European Accreditation, please see next page An application has been made to the EBAC for CME accreditation of this event. Technical facilities Facilities will be available for computer presentations and overhead projections. A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the technicians at least one hour before the session starts. The center will be open at the following times: Thursday, November 27th, from 03.30 p.m. to 08.00 p.m. Friday, November 28th, from 08.00 a.m. to 06.30 p.m. Saturday, November 29th, from 08.00 a.m. to 12.30 a.m. Lunch and coffee breaks Lunch and coffee breaks will be served at Restaurant “Colleoni e dell’Angelo”, walking distance to the congress venue. Abstracts book Participants will receive the Abstracts book at the Meeting. Certificate of attendance The certificate of attendance will be available on request at the end of the Meeting at the Secretariat. – 11 – EBAC ACCREDITATION The event HEART FAILURE AT CROSSROADS is accredited by the European Board for Accreditation in Cardiology (EBAC) for 11 hours of External CME credits (Day #1: 0 CME credits - Day #2: 6 CME credits - Day #3: 5 CME credits). Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. Educational objectives: The goals of this meeting will be to discuss and summarize current status of Heart Failure and to develop a roadmap for clinical practice and research. Determination of educational needs: Worsening HF patients continue to experience unacceptably high mortality and readmission rates that have not changed in recent years. Therefore, it is of utmost importance to re-evaluate what is known, identify what is not known, and develop a roadmap for the improving outcomes through better understanding of the disease process in order to identify unique targets for different HF populations. Target audience: Trained cardiologists, Cardiologists in training CME PROVIDER Azienda Ospedaliera Papa Giovanni XXIII COURSE MEETING DIRECTOR Michele Senni – 12 – LIST OF SPEAKERS, DISCUSSANTS, CHAIRPERSONS AND CO-PRESIDENTS OF THE MEETING Giuseppe Ambrosio Cattedra di Cardiologia Università di Perugia Ospedale S. Maria della Misericordia Perugia (Italy) Marilisa Ambrosio Segreteria Scientifica Dipartimento Cardiovascolare Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Andrew Ambrosy Division of Cardiology Duke University Medical Center Durham, NC (USA) Nadia Aspromonte Azienda Complesso Ospedaliero S. Filippo Neri Rome (Italy) Tiziano Barbui FROM Fondazione per la Ricerca Ospedale Papa Giovanni XXIII Bergamo (Italy) Robert O. Bonow Center for Cardiovascular Innovation Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital Chicago, IL (USA) Javed Butler Division of Cardiology Emory University School of Medicine Atlanta (USA) – 13 – Alice Calabrese Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Ovidiu Chioncel ICCU and Cardiology 1 Department Heart Transplant Program Institute of Emergency for Cardiovascular Diseases C.C. Iliescu Bucharest (Romania) Giovanni Cioffi Cardiologia Villa Bianca Trento Trento (Italy) Emilia D’Elia Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Gaetano Maria De Ferrari Dipartimento Cardiotoracovascolare IRCCS Policlinico San Matteo Pavia (Italy) Renata De Maria Dipartimento Cardiotoracovascolare "A. De Gasperis" Istituto di Fisiologia Clinica del C.N.R. A.O. Ospedale Niguarda Ca' Granda Milan (Italy) Alessandra Dei Cas Dipartimento di Medicina Clinica e Sperimentale Università di Parma Parma (Italy) Andrea Di Lenarda Centro Cardiovascolare ASS1 Triestina Trieste (Italy) Giuseppe Di Tano Cardiologia Azienda Ospedaliera “Istituti Ospitalieri” di Cremona Cremona (Italy) – 14 – Javier Díez Department of Cardiology and Cardiac Surgery Centre for Applied Medical Research University of Navarra Pamplona (Spain) Frank Edelmann Innere Medizin, Kardiologie, Sportmedizin University TS Medizin Göttingen (Germany) Michele Emdin Cardiologia e Medicina Cardiovascolare Fondazione Toscana Gabriele Monasterio CNR-Regione Toscana Pisa (Italy) Maria Frigerio Cardiologia 2 - Insufficienza Cardiaca e Trapianto Dipartimento Cardiotoracovascolare "A. De Gasperis" A.O. Ospedale Niguarda-Ca' Granda Milan (Italy) Antonello Gavazzi FROM Fondazione per la Ricerca Ospedale Papa Giovanni XXIII Bergamo (Italy) Mihai Gheorghiade Division of Cardiology Center for Cardiovascular Quality and Outcomes Northwestern University Feinberg School of Medicine Chicago, IL (USA) Mauro Gori Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Francesco Grigioni Cardiologia Ospedale S. Orsola Università degli Studi di Bologna Bologna (Italy) – 15 – Aurelia Grosu Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Marco Guazzi Heart Failure Unit Università di Milano IRCCS Policlinico San Donato Milan (Italy) Attilio Iacovoni Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Fumiko Inoue Project Organizer Logica Med Elisabeth K. Krainer Department of Cardiology University of Graz & Ludwig - Boltzmann Institute for Translational Heart Failure Graz (Austria) Luca Ferdinando Lorini Anestesia e Rianimazione Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Aldo Pietro Maggioni ANMCO Research Centre Florence (Italy) Marco Metra Cattedra di Cardiologia Spedali Civili e Università di Brescia Brescia (Italy) Andrea Mortara Cardiologia Clinica Unità dello Scompenso e Terapia Intensiva Policlinico di Monza Monza (Italy) – 16 – Carlo Nicora Direzione Generale Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Savina Nodari Cattedra di Cardiologia Spedali Civili e Università di Brescia Brescia (Italy) Fabrizio Oliva Dipartimento Cardiotoracovascolare "A De Gasperis" A.O. Ospedale Niguarda Ca' Granda Milan (Italy) Burkert Mathias Pieske Department of Cardiology University Heart Center Medical University Graz Graz (Austria) Maurizio Porcu Cardiologia Dipartimento Cardio-Toraco-Vascolare Azienda Ospedaliera "G. Brotzu" - San Michele Cagliari (Italy) Naoki Sato Internal Medicine and Cardiology Intensive Care Medicine Nippon Medical School Musashi-Kosugi Hospital Kanagawa (Japan) Michele Senni Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Luigi Tavazzi Direzione Scientifica GVM Care & Research Maria Cecilia Hospital Cotignola, Ravenna (Italy) – 17 – Roberto Trevisan Unità Malattie Endocrine - Diabetologia Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Cheuk-Man Yu Division of Cardiology Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong (China) Alec Vahanian Cardiology Department Hôpital Bichat Paris (France) Claudia Vittori Cardiologia 1 - Scompenso e Trapianti di Cuore Azienda Ospedaliera Papa Giovanni XXIII Bergamo (Italy) Massimo Volpe Divisione di Cardiologia Dipartimento di Medicina Clinica e Molecolare Ospedale Sant'Andrea e Università La Sapienza di Roma Rome (Italy) Adrian A. Voors Department of Cardiology University Medical Center Groningen Groningen (The Netherlands) A Special Thank to A. Menarini I.F.R. for not conditioning financial support – 18 – NOTES – 19 – Menarini Foundation Symposia: 254
© Copyright 2024 Paperzz
